Amandeep Salhotra, MD

Safety and toxicity data from a clinical trial investigating a novel, precision-engineered allo-HSCT conditioning regimen for older patients with high-risk blood cancers.

This session will focus on considerations and outcomes of allo-HSCT specifically among patients over 55 years of age. The panel will discuss how transplant protocols and supportive care measures can be optimized for this population who are at higher risk of comorbidities, toxicity and poor functional status.

An overview of promising novel cellular therapies showing efficacy against hematologic cancers in early-phase clinical trials.

Provide detailed case studies highlighting the development, clinical presentation, multidisciplinary management, and outcomes of patients with acute and chronic GvHD following allo-HSCT.

Focus on methods for preventing graft-versus-host disease (GvHD) following allo-HSCT, such as pharmacologic immune suppression and stem cell graft manipulation techniques.

Summarize ongoing and recently completed clinical trials related to allo-HSCT and associated therapies.

Analyze risks and complications associated with allo-HSCT, including graft-versus-host disease, infections, relapse, and regimen-related toxicities.

This presentation will detail the supportive therapies and interventions provided to patients before, during, and after undergoing allo-HSCT. The speaker will also discuss management of treatment side effects and comorbidities to optimize patient outcomes.

Delve into the pre-transplant conditioning regimens such as chemotherapy and radiation used to prepare and immunosuppress patients to prevent graft rejection prior to allogeneic hematopoietic stem cell transplantation.

Experts discuss what role allogeneic transplants play in hematologic malignancies, specifically in AML and ALL.

Amandeep Salhotra, MD, discusses efficacy data from a phase 1 trial of Orca-Q in acute and chronic graft-vs-host disease.